Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Age: Adult |
Dose: Oral – 90 mg Frequency: once daily Duration: first 7 days Note: As detected by an FDA-approved test. |
|
Indication: Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Age: Adult |
Dose: Oral – 180 mg Frequency: once daily Note: Increase to this dose after the first 7 days. Continue until disease progression or unacceptable toxicity. As detected by an FDA-approved test. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Tablet – No approved pediatric dosage available Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment Mild or moderate (Creatinine Clearance 30-89 mL/min) |
Dose: Tablet – Dosage not specified Note: No dose adjustment required |
|
Condition: Renal impairment Severe (Creatinine Clearance 15-29 mL/min) |
Dose: Tablet – Reduce brigatinib dose by approximately 50% (example: from 180 mg to 90 mg, or from 90 mg to 60 mg) Note: Dosage reduction required for severe renal impairment |
Administration
- Take with or without food
- Take at same time each day
Side Effect
- Increased AST (38%)
- Hyperglycemia (38%)
- Increased ALT (34%)
- Nausea (33%)
- Fatigue (29%)
- Headache (28%)
- Increased CPK (27%)
- Increased amylase (27%)
- Dyspnea (27%)
- Vomiting (24%)
- Anemia (23%)
- Decreased appetite (22%)
- Prolonged aPTT (22%)
- Increased lipase (21%)
- Diarrhea (19%)
- Constipation (19%)
- Lymphopenia (19%)
- Cough (18%)
- Abdominal pain (17%)
- Increased alkaline phosphatase (15%)
- Decreased phosphorous (15%)
- Rash (15%)
- Pyrexia (14%)
- Arthralgia (14%)
- Peripheral neuropathy (13%)
- Muscle spasms (12%)
- Hypertension (11%)
- Pain in extremity (11%)
- Insomnia (11%)
- Back pain (10%)
- Myalgia (9.2%)
- Visual disturbances (7.3%)
- Pneumonia (4.6%)
- Interstitial lung disease/pneumonitis (3.7%)
- Hypoxia (0.9%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Boceprevir, cobicistat, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, grapefruit juice
|
Increased plasma concentration and adverse reactions
|
|
Rifampin, carbamazepine, phenytoin, St. John's Wort
|
Decreased plasma concentration and efficacy
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.